BACKGROUND: Cytomegalovirus (CMV) disease occurs frequently after cessation of antiviral prophylaxis in CMV-seronegative kidney transplant recipients from seropositive donors (D+R-), and the risk factors are incompletely defined. METHOD: We retrospectively assessed the incidence, clinical features, and risk factors for CMV disease in a cohort of D+R- kidney transplant recipients who received antiviral prophylaxis at a single US transplant center using descriptive statistics and Cox proportional hazards models. RESULTS: CMV disease developed in 29 of 113 (26%) D+R- patients at a median of 185 days (interquartile range 116-231 days) post transplant, including CMV syndrome (66%) and tissue invasive disease (34%). The incidence of CMV disease was higher in patients who underwent re-transplantation (57% vs. 24%) and this factor was independently associated with a higher risk of CMV disease in multivariable analysis (hazard ratio, 4.02; 95% confidence interval, 1.3-13; P = 0.016). Other demographic and transplant variables were not independently associated with a risk of late-onset CMV disease. CONCLUSIONS: Despite a comprehensive analysis of patient and transplant variables, only re-transplantation was identified as a risk factor for CMV disease in D+R- kidney transplant recipients who received antiviral prophylaxis, but had limited clinical predictive value. The development of novel laboratory markers to identify patients at greatest risk for CMV disease should be a priority for future studies.
BACKGROUND:Cytomegalovirus (CMV) disease occurs frequently after cessation of antiviral prophylaxis in CMV-seronegative kidney transplant recipients from seropositive donors (D+R-), and the risk factors are incompletely defined. METHOD: We retrospectively assessed the incidence, clinical features, and risk factors for CMV disease in a cohort of D+R- kidney transplant recipients who received antiviral prophylaxis at a single US transplant center using descriptive statistics and Cox proportional hazards models. RESULTS:CMV disease developed in 29 of 113 (26%) D+R- patients at a median of 185 days (interquartile range 116-231 days) post transplant, including CMV syndrome (66%) and tissue invasive disease (34%). The incidence of CMV disease was higher in patients who underwent re-transplantation (57% vs. 24%) and this factor was independently associated with a higher risk of CMV disease in multivariable analysis (hazard ratio, 4.02; 95% confidence interval, 1.3-13; P = 0.016). Other demographic and transplant variables were not independently associated with a risk of late-onset CMV disease. CONCLUSIONS: Despite a comprehensive analysis of patient and transplant variables, only re-transplantation was identified as a risk factor for CMV disease in D+R- kidney transplant recipients who received antiviral prophylaxis, but had limited clinical predictive value. The development of novel laboratory markers to identify patients at greatest risk for CMV disease should be a priority for future studies.
Authors: Michael Boeckh; MeeiLi Huang; James Ferrenberg; Terry Stevens-Ayers; Laurence Stensland; W Garrett Nichols; Lawrence Corey Journal: J Clin Microbiol Date: 2004-03 Impact factor: 5.948
Authors: Ajit P Limaye; Ramasamy Bakthavatsalam; Hyung W Kim; Sara E Randolph; Jeffrey B Halldorson; Patrick J Healey; Christian S Kuhr; Adam E Levy; James D Perkins; Jorge D Reyes; Michael Boeckh Journal: Transplantation Date: 2006-06-27 Impact factor: 4.939
Authors: J C Magee; M L Barr; G P Basadonna; M R Johnson; S Mahadevan; M A McBride; D E Schaubel; A B Leichtman Journal: Am J Transplant Date: 2007 Impact factor: 8.086
Authors: Supha K Arthurs; Albert J Eid; Rachel A Pedersen; Walter K Kremers; Fernando G Cosio; Robin Patel; Raymund R Razonable Journal: Clin Infect Dis Date: 2008-03-15 Impact factor: 9.079
Authors: Alden M Doyle; Karen M Warburton; Simin Goral; Emily Blumberg; Robert A Grossman; Roy D Bloom Journal: Transplantation Date: 2006-04-27 Impact factor: 4.939
Authors: K Solez; R A Axelsen; H Benediktsson; J F Burdick; A H Cohen; R B Colvin; B P Croker; D Droz; M S Dunnill; P F Halloran Journal: Kidney Int Date: 1993-08 Impact factor: 10.612
Authors: Enver Akalin; Vinita Sehgal; Scott Ames; Sabera Hossain; Lisa Daly; Murphy Barbara; Jonathan S Bromberg Journal: Am J Transplant Date: 2003-06 Impact factor: 8.086
Authors: Nina Singh; Drew J Winston; Raymund R Razonable; G Marshall Lyon; Fernanda P Silveira; Marilyn M Wagener; Terry Stevens-Ayers; Bradley Edmison; Michael Boeckh; Ajit P Limaye Journal: JAMA Date: 2020-04-14 Impact factor: 56.272
Authors: Carlos A Q Santos; Daniel C Brennan; Mohammed J Saeed; Victoria J Fraser; Margaret A Olsen Journal: Clin Transplant Date: 2016-03-04 Impact factor: 2.863
Authors: Isabel Pérez-Flores; Jose Luis Santiago; Cristina Fernández-Pérez; Elena Urcelay; María Ángeles Moreno de la Higuera; Natividad Calvo Romero; Beatriz Rodríguez Cubillo; Ana Isabel Sánchez-Fructuoso Journal: Open Forum Infect Dis Date: 2019-07-20 Impact factor: 3.835